Inventor
ZHANG FENGLEI
US31 patents
⚠️ This page may combine multiple inventors who share the name “ZHANG FENGLEI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INCYTE CORP
30 patentsUS10450313B2Oct 22, 2019
Bicyclic heterocycles as FGFR inhibitors
INCYTE CORP32 citations98
US10040790B2Aug 7, 2018
Bicyclic heterocycles as FGFR inhibitors
INCYTE CORP36 citations98
US9533984B2Jan 3, 2017
Bicyclic heterocycles as FGFR inhibitors
INCYTE CORP42 citations98
US11407749B2Aug 9, 2022
Heterocyclic compounds as immunomodulators
INCYTE CORP23 citations94
US11339149B2May 24, 2022
Heterocyclic compounds as immunomodulators
INCYTE CORP24 citations94
US10947230B2Mar 16, 2021
Bicyclic heterocycles as FGFR inhibitors
INCYTE CORP26 citations94
US10800768B2Oct 13, 2020
Heterocyclic compounds as immunomodulators
INCYTE CORP30 citations94
US10174030B2Jan 8, 2019
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP14 citations94
US9944647B2Apr 17, 2018
Heterocyclic compounds as LSD1 inhibitors
INCYTE CORP30 citations94
US9670210B2Jun 6, 2017
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP23 citations94
US9493442B2Nov 15, 2016
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP30 citations94
US7723349B2May 25, 2010
Aza spiro alkane derivatives as inhibitors of metalloproteases
INCYTE CORP21 citations93
US11613536B2Mar 28, 2023
Heterocyclic compounds as immunomodulators
INCYTE CORP15 citations86
US11530214B2Dec 20, 2022
Bicyclic heterocycles as FGFR inhibitors
INCYTE CORP7 citations86
US11465981B2Oct 11, 2022
Heterocyclic compounds as immunomodulators
INCYTE CORP18 citations86
US10300051B2May 28, 2019
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP14 citations86
US10800779B2Oct 13, 2020
Heterocyclic compounds as LSD1 inhibitors
INCYTE CORP6 citations84
US10717737B2Jul 21, 2020
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP7 citations84
US9801877B2Oct 31, 2017
AZA spiro alkane derivatives as inhibitors of metalloproteases
INCYTE CORP7 citations84
US11673894B2Jun 13, 2023
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
INCYTE CORP4 citations74
US8039471B2Oct 18, 2011
Aza spiro alkane derivatives as inhibitors of metalloproteases
INCYTE CORP5 citations74
US11247992B2Feb 15, 2022
Cyclopropylamines as LSD1 inhibitors
INCYTE CORP3 citations73
US9403775B2Aug 2, 2016
AZA spiro alkane derivatives as inhibitors of metalloproteases
INCYTE CORP3 citations73
US11472791B2Oct 18, 2022
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
INCYTE CORP7 citations72
US11229631B2Jan 25, 2022
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
INCYTE CORP0 citations63
US11873309B2Jan 16, 2024
Heterocyclic compounds as immunomodulators
INCYTE CORP1 citations62
US11401272B2Aug 2, 2022
Heterocyclic compounds as LSD1 inhibitors
INCYTE CORP0 citations62
US12378243B2Aug 5, 2025
Quinoline compounds as inhibitors of KRAS
INCYTE CORP0 citations56
US12516044B2Jan 6, 2026
Heterocyclic compounds as immunomodulators
INCYTE CORP0 citations52
US10226459B2Mar 12, 2019
Aza spiro alkane derivatives as inhibitors of metalloproteases
INCYTE CORP0 citations52